The Swedish pharmaceutical market is one of the most progressive markets in the EU. Valued at 4.3 billion euros in 2019, Sweden's pharmaceutical market is 8th by size in Europe, with export of medicines listed at over 100 billion SEK (10B$) in 2021. Sweden spends about 11% of GDP on health and medical services and is set to register a CAGR of 3.9% over the forecast period (2022-2027).
Medical suppliers for the Swedish healthcare system are selected via a tendering process, in which the suppliers submit an application providing evidence of clinical effectiveness alongside their price, thus creating a competitive market. The procurement process is done within governmental framework agreements, used to supply basic terms and conditions that are withheld between the regions and the selected suppliers. The responsibility for health and medical care in Sweden is shared by the central government, in charge of approving reimbursement, the regions, and the municipalities. Sweden is divided into 21 regions, responsible for providing and procuring medicines and other medical services. They are also responsible for the distribution of resources to health services and for the overall planning of the services offered. The regions own and run the hospitals, health centers, and other institutions as well.
Pharma14 tracks the Swedish tender market closely.

Sample Pharma14 data: Pfizer's Benefix Coagulation factor IX pricing at tender vs. standard levels.